Wang MX, Zhu P, Shi Y, Sun QM, Dong WH. Returning from the afterlife? Sotorasib treatment for advanced KRAS mutant lung cancer: A case report. World J Clin Cases 2024; 12(25): 5805-5813 [DOI: 10.12998/wjcc.v12.i25.5805]
Corresponding Author of This Article
Wan-Hui Dong, MD, Chief Doctor, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, No. 76 Renmin Road, Lu’an 237000, Anhui Province, China. dongwanhui@laszyy.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Ming-Xing Wang, Pei Zhu, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine Affiliated to Anhui University of Chinese Medicine, Lu’an 237000, Anhui Province, China
Yue Shi, Qing-Ming Sun, Wan-Hui Dong, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, Lu’an 237000, Anhui Province, China
Author contributions: Wang MX, Zhu P, Shi Y, Sun QM, and Dong WH designed the research study; Wang MX and Dong WH performed the research; Zhu P, Shi Y, and Sun QM contributed new reagents and analytic tools; Wang MX and Dong WH analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wan-Hui Dong, MD, Chief Doctor, Department of Medical Oncology, Lu’an Hospital of Traditional Chinese Medicine, No. 76 Renmin Road, Lu’an 237000, Anhui Province, China. dongwanhui@laszyy.cn
Received: April 19, 2024 Revised: June 22, 2024 Accepted: June 28, 2024 Published online: September 6, 2024 Processing time: 88 Days and 1.8 Hours
Abstract
BACKGROUND
Lung cancer is increasing in incidence worldwide, and targeted therapies are developing at a rapid pace. Furthermore, the KRAS specific gene is strongly associated with non-small cell lung cancer (NSCLC). Adult patients with locally advanced or metastatic NSCLC who have tested positive for the KRAS G12C mutation and have progressed after at least one systemic treatment are treated with sotorasib.
CASE SUMMARY
In this study, we report on an advanced NSCLC with a KRAS G12C mutation. The histological diagnosis indicates stage IVB left lung adenocarcinoma with pelvic and bone metastases, identified as cT4N2bM1c. Using circulating tumor DNA analysis, it was possible to determine the mutation abundance of the KRAS gene exon 2, c.34G > Tp.G12C, which was 32.3%. The patient was advised to take sotorasib as part of their treatment. The imaging data were compared before and after treatment. Furthermore, clinical reassessments and regular serial blood testing were conducted. We found that the patient’s clinical symptoms significantly improved after receiving sotorasib medication, and there were no notable side effects, such as liver toxicity, during the treatment.
CONCLUSION
Sotorasib has shown promising clinical efficacy in patients with the KRAS G12c mutation and has no apparent toxic side effects.
Core Tip: In this study, we demonstrate the efficacy of sotorasib in treating advanced non-small cell lung cancer with the KRAS G12C mutation. A patient diagnosed with stage IVB adenocarcinoma, exhibiting pelvic and bone metastases, showed a significant improvement in clinical symptoms post-sotorasib treatment, with no severe side effects observed. This case highlights the potential of targeted therapies in personalized cancer treatment, emphasizing the importance of genomic profiling for therapeutic decision-making.
